Iovance Biotherapeutics Reports Third Quarter 2026 Financial Results

Iovance Biotherapeutics reported record third-quarter 2026 revenue of approximately $122 million, driven by continued strong U.S. demand for its Amtagvi therapy. The company also said it achieved its highest gross margin to date. The report did not provide profit figures or stock-price movements.